Korro Bio (KRRO)

• Market cap: $320M
• 1 day: -0.18%
• 5 days: -9.59%
• 1 month: -10.38%
• 3 months: -40.66%
• 6 months: -26.72%
• Year to date: -16.82%
• 1 year: -32.85%
• 5 years: 42.70%
• 10 years: 149.05%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Employees: 101

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 8

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

11% more funds holding

Funds holding: 64 [Q2] → 71 (+7) [Q3]

0.75% more ownership

Funds ownership: 91.18% [Q2] → 91.93% (+0.75%) [Q3]

0% less capital invested

Capital invested by funds: $286M [Q2] → $286M (-$553K) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $115 237% upside
• Avg. target: $123 259% upside
• High target: $130 281% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 29% 1-year accuracy 49 / 168 met price target	237% upside $115	Buy Reiterated	22 Nov 2024
Jones Trading Catherine Novack 30% 1-year accuracy 3 / 10 met price target	281% upside $130	Buy Initiated	18 Nov 2024